British Society for Rheumatology guideline on the management of SLE

  • Rheumatology (Oxford)

  • from Dawn O'Shea
  • Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.


  • First UK-based guidelines for the diagnosis and management of systemic lupus erythematosus (SLE).

Why this matters

  • SLE affects nearly 1 in 1000 people in the United Kingdom. 

Key recommendations

  • Antiphospholipid antibodies (aPLs) should be tested in all patients at baseline. 
  • Confirmatory tests for antiphospholipid syndrome (APS) are positive lupus anticoagulants, anti-cardiolipin antibody and/or anti-beta-2 glycoprotein-1 on 2 occasions ≥12 wk apart. 
  • Patients with active disease should be reviewed at least every 1-3 mo. 
  • Patients with low disease activity or in remission can be reviewed every 6-12 mo. 
  • Presence of aPLs in previously negative patients warrants re-evaluation prior to pregnancy or surgery, or in the presence of new severe manifestation or vascular event. 
  • Check anti-Ro and anti-La antibodies prior to pregnancy. 
  • Treatment of mild disease includes hydroxychloroquine (Plaquenil, Quinoric) and methotrexate (Ebetrex, Maxtrex, Metoject), and short courses of NSAIDs for symptom control. 
  • Prednisolone ≤7.5 mg/d may be required for maintenance.
  • Prednisolone ≤0.5 mg/kg/d or intramuscular/intravenous methylprednisolone for moderate disease. 
  • Consider methotrexate, azathioprine (Imuran), mycophenolate mofetil (Cellcept), ciclosporin (Neoral, Sandimmun Deximune), and other calcineurin inhibitors for arthritis, cutaneous disease, serositis, vasculitis or cytopenias if hydroxychloroquine is insufficient. 
  • For refractory cases, belimumab (Benlysta) or rituximab (Truxima, MabThera) may be considered. 
  • Patients with severe SLE should receive immunosuppression and/or anticoagulation. 
  • Mycophenolate mofetil or ciclosporin for lupus nephritis and refractory, severe non-renal disease. 
  • Consider belimumab where immunosuppressives fail or are poorly tolerated. 
  • Consider intravenous immunoglobulin and plasmapheresis for refractory cytopenias, thrombotic thrombocytopenic purpura, rapidly deteriorating acute confusional state and catastrophic APS.